Ahaneku J E
Department of Chemical Pathology, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria.
Acta Med Okayama. 1996 Apr;50(2):107-10. doi: 10.18926/AMO/30491.
Fasting blood glucose was determined in 27 adults with essential hypertension at four different periods during a 12-month treatment with doxazosin, an alpha-adrenoceptor antagonist, and in another set of 20 adult hypertensive patients, after 3 months treatment with amlodipine, a calcium antagonist. The mean fasting blood glucose levels at various determinations during doxazosin therapy did not show any significant variation from the pre-treatment value. Similarly, mean fasting blood glucose level remained the same after 3 months of amlodipine therapy. The findings, therefore, highlights the safety of doxazosin and amlodipine antihypertensive pharmacotherapies.
在27名原发性高血压成年患者接受α-肾上腺素受体拮抗剂多沙唑嗪12个月治疗的四个不同时间段测定空腹血糖，并在另一组20名成年高血压患者接受钙拮抗剂氨氯地平治疗3个月后测定空腹血糖。多沙唑嗪治疗期间各次测定的平均空腹血糖水平与治疗前值相比无显著变化。同样，氨氯地平治疗3个月后平均空腹血糖水平保持不变。因此，这些发现突出了多沙唑嗪和氨氯地平抗高血压药物治疗的安全性。
